Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BCX-1777 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| BCX-1777 | DRUG | - |
Inclusion Criteria: * Previously treated, relapsed or refractory aggressive T-cell malignancies (leukemias and lymphomas) histologically proven with measurable disease. * Capable of only limited self-care, confined to bed or chair more than 50% of waking hours. * All ages are eligible. Pediatric pa...
BCX-1777 is an investigational small molecule being studied for the treatment of leukemia and lymphocytic lymphoma. It was evaluated in a Phase 1 clinical trial for patients with relapsed or refractory aggressive T-cell leukemias or lymphomas. The drug is still in clinical development and is not approved by the FDA.
BCX-1777 is being developed by BioCryst Pharmaceuticals, Inc., a biopharmaceutical company traded on the stock exchange under the ticker symbol BCRX. The company conducted a Phase 1 clinical trial of the drug in the United States for the treatment of certain leukemias and lymphomas.
BCX-1777 is in Phase 1 clinical development. A single Phase 1 trial has been completed, which enrolled 71 participants. The drug remains investigational and has not received FDA approval. No active clinical trials are currently listed for BCX-1777.
BCX-1777 was studied in a completed Phase 1 clinical trial with the identifier NCT00035022. The trial was titled 'Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas' and enrolled 71 participants in the United States. The study was uncontrolled and not randomized.
BCX-1777 is not FDA approved. It is an investigational drug that has only been studied in a Phase 1 clinical trial, which has been completed. The drug is still in clinical development and has not been approved for any medical use.